-
Sodium Picosulfate in Gut–Brain Axis Research
2026-09-20
Sodium Picosulfate offers a defined intestinal perturbation for constipation and gut–brain axis studies. This article connects its electrolyte and fluid effects with regional PET imaging, assay controls, and translational limitations in chronic hepatic encephalopathy research.
-
Novel Allosteric PDK4 Inhibitors for Metabolic Disease
2026-09-19
Jeon and colleagues identified an anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors and found compound 8c to combine strong biochemical activity with favorable early pharmacokinetic properties. In diet-induced obesity, allergic inflammation, and cancer-related cellular assays, 8c produced disease-relevant effects, although the findings remain preclinical and require broader validation.
-
Angiotensin I: Workflows for Cardiovascular Research
2026-09-18
Use Angiotensin I as a controlled substrate for mapping ACE-dependent signaling, screening antihypertensive candidates, and separating precursor conversion from direct receptor activation. This workflow combines practical peptide handling with spectral quality-control lessons from a recent fluorescence-classification study.
-
Spatially Concentrated Base Editors Correct PLP1
2026-09-18
This study introduces spatially concentrated adenine base editors that improve editing in oligodendrocytes by enriching TadA* near genomic targets rather than simply increasing catalytic expression. The AAV-compatible cABE-2.0 system corrected PLP1 A243V, reduced transcriptome-wide RNA off-target effects, and improved myelination-related phenotypes in experimental models of Pelizaeus–Merzbacher disease.
-
NHS-Biotin for Nanobody Protein Workflows
2026-09-17
NHS-Biotin adds a stable biotin handle to antibodies, nanobodies, and intracellular proteins for streptavidin-based detection or purification. This workflow also shows how to characterize peptidisc-stabilized protein assemblies without confusing assay labeling with the mechanism that creates multimerization.
-
Full-Length αvβ3 Integrin Cryo-EM Structural Diversity
2026-09-17
The reference study uses high-resolution cryo-EM to resolve full-length human αvβ3 integrin across six apo conformations and five ligand-bound states, including five previously uncharacterized intermediates. Its continuum model clarifies how inhibitors engage distinct receptor conformations and provides a structural basis for more selective integrin drug design.
-
DHEA in PCOS: From Model to Assay Insight
2026-09-16
Explore how Dehydroepiandrosterone (DHEA) can be interpreted as an immune-context perturbation in PCOS research, rather than simply an ovarian stressor. This guide connects macrophage CD163 biology, granulosa-cell apoptosis, product handling, and assay design.
-
Cy3 NHS ester (non-sulfonated): Practical Guide
2026-09-16
Cy3 NHS ester (non-sulfonated) provides an orange fluorescent tag for amino-group labeling of proteins, peptides, and oligonucleotides when an organic co-solvent is acceptable. It should not be selected for strictly aqueous workflows or delicate proteins that may be affected by DMSO or DMF.
-
ML385: A Practical NRF2 Inhibitor Workflow
2026-09-15
ML385 enables controlled NRF2 signaling pathway inhibition in cancer models, helping researchers separate adaptive antioxidant responses from drivers of therapeutic resistance. This workflow connects target engagement, oxidative stress modulation, ferroptosis-associated assays, and combination studies across NSCLC and emerging pancreatic cancer models.
-
Palmitic acid (N2456): Practical Protocol & QC
2026-09-15
Palmitic acid (SKU N2456) provides a characterized saturated long-chain fatty acid input for controlled lipid, metabolic, inflammatory, and signaling workflows. Because it is insoluble in water and solutions are not intended for long-term storage, use a validated ethanol or DMSO preparation with matched vehicle controls and prompt use.
-
Tofacitinib Repairs RA Macrophage Dysfunction
2026-09-14
The 2026 reference study identifies GM-CSF-reprogrammed rheumatoid arthritis macrophages as an inflammatory state coupled to oxidative stress, mitochondrial fragmentation, and metabolic imbalance. It shows that Tofacitinib reverses this linked pathology more broadly than complex I or glucose-uptake inhibition by reducing GM-CSFRα expression, suppressing STAT5 signaling, and restoring regulatory and mitochondrial features.
-
Naftifine HCl: Applied Antifungal Workflows
2026-09-14
Build more informative antifungal experiments with Naftifine HCl by pairing growth inhibition with membrane, sterol-pathway, and time-course readouts. This workflow also translates the multidimensional assay logic of muscle-cell signaling research into a practical framework for fungal mechanism studies without conflating the two biological systems.
-
Canagliflozin: Kidney–Mitochondria Framework
2026-09-13
Canagliflozin is a selective SGLT2 inhibitor whose research value extends beyond glucose lowering into proximal-tubule mitochondrial phenotyping. This evidence-led framework explains how to connect renal glucose reabsorption inhibition with bioenergetic, structural, and sex-aware assay decisions.
-
Clodronate Liposomes: In Vivo Macrophage Workflows
2026-09-12
Clodronate Liposomes provide a practical loss-of-function tool for testing whether macrophages drive tissue injury or treatment response. This guide translates hepatic ischemia-reperfusion findings into controlled depletion workflows, assay controls, and troubleshooting decisions.
-
Bufuralol hydrochloride for Organoid PK
2026-09-11
Bufuralol hydrochloride connects β-adrenergic receptor pharmacology with human pluripotent stem cell-derived intestinal organoids, enabling studies that pair receptor modulation with absorption, metabolism, and transporter readouts. This workflow offers a human-relevant complement to conventional animal and Caco-2 models while preserving practical controls for solvent effects, exposure timing, and partial agonist behavior.